enGene Therapeutics Inc. (ENGN)
enGene Therapeutics develops genetic medicines, led by detalimogene, a product candidate for a type of bladder cancer. It last closed at $1.72 on Nov 17, down 8.99% on the day. ENGN reports earnings on Tue, Dec 22, 2026. The average 12-month price target from 3 analysts is $5.00 (+190.7% from the last close), with a high of $6.00 and a low of $4.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From ENGN's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 8). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on ENGN in the past 90 days. The average target is $5.00, with a high of $6.00 and a low of $4.00, compared with the last close of $1.72.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Leerink Partners | Upgrade | Buy | $5 |
| Nov 12 | Wells Fargo | Upgrade | Buy | $2 → $6 |
| Sep 8 | HC Wainwright & Co. | Reiterated | Buy | $4 |
| Jun 16 | HC Wainwright & Co. | Maintained | Buy | $4 |
| May 8 | Wells Fargo | Downgrade | Hold | $2 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 125% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the swing low (Jul 29) at $1.71, and the nearest resistance the swing high (Oct 16) at $1.75.
| RSI (14) | 48.15 | Middle of its range | Neutral |
| MACD | 0.07 | Above its signal line | Bullish |
| Stochastic | 52.5 | Middle of its range | Neutral |
| ADX (14) | 23.5 | Weak trend | |
| Williams %R | -74.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 26.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +6.2% | Change over 10 sessions | Bullish |
| ATR (14) | $0.18 | Typical daily range, 10.7% of price |
| RSI (14) | 39.57 | Weak, oversold below 30 | Neutral |
| MACD | -0.59 | Above its signal line | Bullish |
| Stochastic | 54.5 | Middle of its range | Neutral |
| ADX (14) | 26.8 | Trending up | |
| Williams %R | -74.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 64.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −4.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.49 | Typical daily range, 28.5% of price |
What happened before
See how ENGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ENGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in ENGN in the last 90 days.
ENGN Institutional Ownership
Full report →- ▼28 buying vs 34 selling
- ▼Held by funds -1.1 pts
- ▲Funds holding +2
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 58 | 56 | +3.6% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 56.4% | 57.5% | −1.1 pts |
| New / increased | 17 / 11 | 55 / 0 | −49.1% |
| Reduced / sold out | 19 / 15 | 0 / 1 | +3300.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENGN is in one of them and how their past ENGN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ENGN in an article yet. Here's the latest on the wider market.
About enGene Therapeutics
enGene Therapeutics is a biotechnology company based in Saint-Laurent that develops genetic medicines. Its main product candidate, detalimogene, is intended for patients with a form of bladder cancer that no longer responds to BCG treatment. The company is also building a delivery platform that carries genetic medicines to mucosal tissues, with plans to apply it to other conditions such as urogenital and gastrointestinal diseases. Its products are still in preclinical and clinical development and are not yet approved for sale.
- Headquarters
- Saint-Laurent



